Biogen (BIIB) Receives a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Biogen price target lowered to $160 from $190 at Citi
Citi analyst Geoff Meacham lowered the firm’s price target on Biogen (BIIB) to $160 from $190 and keeps a Neutral rating on the shares. Ahead ...
FiercePharma21 天
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
Biogen has offered to purchase Sage’s outstanding shares for $7.22 each, according to a securities filing from Friday. The proposal values Sage at around $442 million. A yearslong partner of ...
pharmaphorum5 天
Biogen go quantum to speed up drug development
“At Biogen, we’re always looking to harness cutting-edge technologies that push the boundaries of traditional pharmaceutical research to discover new treatments and cures for complex ...
FiercePharma6 天
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics ... confirmed in a statement to Fierce Pharma last week. In the companies' original pact ...